Tag
Genetic variants in dilated cardiomyopathy confer differential arrhythmic risks, independent of traditional clinical parameters. Integrating recent registry data and molecular studies enhances risk stratification and informs tailored manage
A gene-specific, risk-based screening algorithm for relatives with titin-truncating variants optimizes monitoring intervals from 1 to 5 years, improving safety and resource use in dilated cardiomyopathy surveillance.
This article reviews novel research showing how cytoplasmic mislocalization of RBM20 impairs mitochondrial function, leading to severe dilated cardiomyopathy and highlighting distinct mechanisms between gain- and loss-of-function RBM20 vari
This study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,
The 2024 update of the Clinical Genome Resource elucidates a rapidly expanding genetic landscape for dilated cardiomyopathy, enhancing clinical genetic interpretation with 35 genes classified as high evidence, including nine novel discoveri
This study reveals that two-thirds of community sudden cardiac deaths occur in individuals without diagnosed cardiac disease, with half harboring occult myocardial infarction or dilated cardiomyopathy, underscoring the need for improved det
This study reveals that left ventricular hypertrabeculation, common in dilated cardiomyopathy, does not increase embolic risk or adverse outcomes, challenging previous concerns and guiding clinical management.
This study highlights the role of RBM20 truncating variants in arrhythmogenic dilated cardiomyopathy, showing reduced penetrance and milder disease severity compared to pathogenic missense variants and titin truncating variants.
This review explores the transition of genetic testing in dilated cardiomyopathy from family risk assessment to a central tool for clinical decision-making and personalized risk stratification.
Recent research identifies LOXL2 as a primary driver of fibrosis in LMNA-mutated dilated cardiomyopathy. The study demonstrates that Simtuzumab, a LOXL2 inhibitor, effectively prevents extracellular matrix remodeling and preserves cardiac f
A Phase 2 trial demonstrates that danicamtiv, a novel cardiac myosin agonist, significantly improves left ventricular function in patients with genetic forms of dilated cardiomyopathy, particularly those with MYH7 and TTN variants, signalin
An international multicenter study reveals that while Titin-truncating variants significantly increase cardiomyopathy risk, disease onset is heavily influenced by male sex, co-morbidities, and atrial fibrillation, while early prophylactic t
A landmark Spanish study reveals that patients with ‘arrhythmic’ genotypes in dilated cardiomyopathy face a significantly higher risk of advanced heart failure events, including heart transplantation and VAD implantation, necess
A focused guide to modern genetic and clinical screening of relatives after a dilated cardiomyopathy diagnosis, summarizing the 2025 clinical consensus and practical steps for clinicians and families.
Desmoplakin gene variants confer a higher risk and penetrance of dilated cardiomyopathy in females, contrasting with male-predominant risks from other genes like TTN. This discovery underscores sex-specific mechanisms in DCM susceptibility
